AllSight
Companies · ALMS · Pharmaceutical Preparations

ALUMIS INC. (ALMS)

ALUMIS INC. (ALMS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

ALUMIS INC. (ALMS) stock — financials & valuation

Key numbers for ALUMIS INC. (ALMS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 35/100 — a percentile rank of ALUMIS INC.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$956.5M
P / S129.3×
EV / EBITDA-2.2×
Gross margin100.0%
Operating margin-6204.4%
Net margin-5933.5%
Return on equity-97.1%
ROIC-117.7%
Revenue growth-63.1%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from ALUMIS INC.’s own financial statements and shown as context, never as advice.

Sep 1, 2026Below the bar
Alumis lupus trial misses endpoints as IFNGS-high subgroup offers a rescue path
Aug 13, 2026Miss
Promising psoriasis data cannot hide a sharp revenue miss and pipeline write-down
Aug 10, 2026
Long-term psoriasis data deepen clearance, keeping NDA path on track
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact